SCHEMBL7429793

SCHEMBL7429793

CCCC(=O)Oc1ccc(C(=O)CCc2ccccc2)c([N+](=O)[O-])c1OC(=O)CCC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 12/20 0.42
TSHR P16473 2/20 0.41
BCL9 O00512 1/20 0.41
CTNNB1 P35222 1/20 0.41
LMNA P02545 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
KCNK3 O14649 1/20 0.40
SLC22A1 O15245 1/20 0.40
ABCC9 O60706 1/20 0.40
KCNK2 O95069 1/20 0.40
ABCB11 O95342 1/20 0.40
ADRB2 P07550 1/20 0.40
ADRB1 P08588 1/20 0.40
ADRB3 P13945 1/20 0.40
ADRA2C P18825 1/20 0.40
SLC6A2 P23975 1/20 0.40
HTR2A P28223 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7431099 0.94 BCL9 (0.39) ABCB1BCL9CTNNB1ALDH1A1MAPT
SCHEMBL7429291 0.90 BCL9 (0.41) TSHRBCL9CTNNB1LMNAALDH1A1
SCHEMBL7429279 0.84 ABCB1 (0.47) ABCB1TSHRLMNAALDH1A1MAPT
SCHEMBL6572279 0.83 BCL9 (0.43) ABCB1BCL9CTNNB1LMNAALDH1A1
SCHEMBL7432671 0.79 NPC1 (0.41) LMNAALDH1A1MAPTADRA1ASLC6A3
SCHEMBL7437517 0.78 ABCB1 (0.40) ABCB1ALDH1A1MAPTMEN1KMT2A
SCHEMBL7429307 0.77 BCL9 (0.41) ABCB1BCL9CTNNB1LMNACYP1A2
SCHEMBL7513057 0.74 PTPN1 (0.43) TSHRLMNACYP1A2CYP2D6ALDH1A1
SCHEMBL7425246 0.72 MAPT (0.36) ABCB1LMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL7432620 0.71 CYP1A1 (0.51) ABCB1LMNAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them PORTELA & C.A., S.A. (PT) 2002-03-28 US claimed
EP-1167341-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them Portela & Ca., S.A. (PT) 2002-01-02 EP claimed
WO-2001098250-A1 SUBSTITUTED NITRATED CATECHOLS, THEIR USE IN THE TREATMENT OF SOME CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PORTELA & CA SA (PT) 2001-12-27 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them SLC6A2, COMT, SLC6A3 ABCB1 210/4885TSHR 3223/4885BCL9 4557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.